|Bid||7.75 x 5000|
|Ask||7.93 x 200|
|Day's Range||7.76 - 8.28|
|52 Week Range||4.10 - 15.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 2, 2018 - Apr 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.80|
A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.
Five opioid manufacturers including OxyContin maker Purdue Pharma LP have paid more than $10 million to advocacy groups and doctors tied to them, many of whom amplified industry messages supporting the use of the painkillers, a U.S. Senate report said on Monday. The report, released by Democratic Senator Claire McCaskill, said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42,000 opioid overdose deaths. The report released by McCaskill, the U.S. Senate Homeland Security and Governmental Affairs Committee's ranking Democrat, said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use.
PHOENIX, Feb. 09, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement ...
Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine. Maryland Attorney General Brian Frosh confirmed on Thursday that his office filed a lawsuit in state court after Insys resisted turning over documents sought as part of an investigation into the drugmaker's role in the opioid epidemic. Frosh said the state had been investigating the Chandler, Arizona-based company since 2016 amid allegations that Insys had marketed its product Subsys to not just patients with severe cancer pain but for other conditions.
The U.S. stock markets had their worst week in months last week, ending with the biggest loss since President Donald Trump took office on Friday. The plunge came after U.S. jobs figures were announced ...
In this article we are going to present an alternative to weed stocks such as GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), Cara Therapeutics Inc (NASDAQ:CARA), Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), and Insys Therapeutics Inc (NASDAQ:INSY). When it comes to investing in the marijuana industry many people think about stocks of companies that are either growing and/or selling […]
Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses. New York Attorney General Eric Schneiderman alleged that the Chandler, Arizona-based drugmaker recklessly marketed its product Subsys for wider uses than the U.S. Food and Drug Administration approved and bribed doctors to prescribe it. "At a time when the opioid epidemic was ravaging New York, Insys Therapeutics allegedly marketed a drug illegally by blatantly disregarding the grave risks of addiction and death that opioids pose," Schneiderman said in a statement.
PHOENIX, Feb. 01, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released the following statement ...
PHOENIX, Feb. 01, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the appointment of ...
VP of Human Resources, Carol Summersgill; VP of Clinical Development, Dr. PHOENIX, Jan. 30, 2018-- INSYS Therapeutics, Inc., a leader in the development, manufacture and commercialization of pharmaceutical ...
In the earlier part of this series, we briefly discussed why investors have recently rushed into cryptocurrencies and marijuana. In this part, we’ll discuss the difference between these investment opportunities, starting with the marijuana industry (MJX). Businesses exist to provide value to an end user, and marijuana’s end use has been fairly well-established. There has been an established market for medical marijuana in several countries.
One of the consequences of cannabis remaining federally illegal is the lack of unified standards for operating businesses. Every state, municipality and jurisdiction compels marijuana businesses to fulfill ...
In the previous article in this series, we saw that Vermont decriminalized recreational marijuana on January 22, 2018. With no legality covering the sale of marijuana and no tax revenues from these sales, what would motivate Vermont to legalize recreational marijuana?
On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.
In the previous part of this series, we saw how the legalization of recreational marijuana could create related business opportunities. In this part, we’ll discuss the potential upside of recreational marijuana for a country like Canada. According to Deloitte, recreational marijuana alone could be a $5 billion industry initially, and it could go as high as $8.7 billion.
In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.
In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy. With too much confusion surrounding the legalities of the marijuana industry, some seasoned players appear highly optimistic about the future of recreational marijuana. Late last year, Constellation Brands (STZ) agreed to acquire a 9.9% stake in the Canada-based Canopy Growth for about $191.3 million.
In this part, we look at the secondary use of marijuana, recreational use. In mid-2018, Canada is expected to make marijuana legal for recreational use. This outlook has been driving stocks such as Aurora Cannabis (ACB.TO), Canopy Growth (WEED.TO), Aphria (APH.TO), and MedReleaf (LEAF.TO) to new highs.
It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014. Globally, the acceptance of marijuana evolved further in 2017 with more countries either legalizing cannabis access at a federal level or exploring the possibility of legalizing cannabis.
The state of Colorado has released its 2017 legal cannabis tax data, reporting collections of $247.36 million, up from $193.6 million in 2016. Based on these figures, financial analysis and research firm ...